This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Comparison of Endoscopic Variceal Ligation (EVL) With Propranolol in Non Cirrhotic Portal Hypertension (NCPH)

This study has been completed.
Information provided by:
Govind Ballabh Pant Hospital Identifier:
First received: October 22, 2009
Last updated: December 21, 2010
Last verified: October 2009

Background: Variceal bleeding is a major cause of morbidity and mortality in patients with Non Cirrhotic Portal Hypertension (NCPH). Beta blockers (BB) and endoscopic variceal ligation (EVL) have been used to prevent rebleeding in these patients, largely based on data from cirrhotic patients. Endotherapy in the form of EST has been well studied in preventing rebleed in patients with NCPH. Initial studies showed that EST significantly reduced the rebleeding rate in patients of NCPH. Data from these studies suggests a rebleed rate of approximately 25% at 2yr and 35% at 5 years.

Beta blockers have been found to be quite effective in both primary as well as secondary prophylaxis of variceal bleeding in cirrhotic and are accepted mode of treatment. In contrast to liver cirrhosis, published data on the effect of beta blocker therapy on NCPH are scanty. Animal data and human data suggests that beta blockers reduce portal pressure in patients with NCPH. In two placebo controlled trials of propranolol on secondary prophylaxis of variceal bleeding in non cirrhotic patients. both studies demonstrated the efficacy of propranolol in decreasing rebleed rate. However, no comparisons hae been made with EVL till date.

Hypothesis: The investigators hypothesis that In patients with NCPH, treatment with beta blockers will lead to reduction in portal pressure and decrease in portosystemic shunting leading to reduction in variceal rebleeding Aim of the study: Aim: To compare the efficacy and safety of Propranolol and EVL in the prevention of variceal rebleeding in patients with NCPH.

Condition Intervention Phase
Non Cirrhotic Portal Hypertension Drug: Propranolol Device: multi band ligator for esophageal varices Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Comparison of Endoscopic Variceal Ligation (EVL) and Propranolol in Secondary Prophylaxis of Variceal Bleeding in Patients With Non Cirrhotic Portal Hypertension (NCPH): A Prospective Randomized Controlled Trial

Resource links provided by NLM:

Further study details as provided by Govind Ballabh Pant Hospital:

Primary Outcome Measures:
  • Rebleed, death [ Time Frame: At least 3 months after last enrollment ]

Secondary Outcome Measures:
  • Adverse effects of EVL or drug therapy, variceal eradication on EVL, variceal recurrence after eradication on EVL, decrease in variceal grade in the propranolol limb [ Time Frame: At least 3 months after last enrollment ]

Estimated Enrollment: 100
Study Start Date: January 2005
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Endoscopic Variceal Ligation
endoscopic therapy to obliterate varices
Device: multi band ligator for esophageal varices
to obliterate esophageal varices
Active Comparator: Propranolol
drugs to decrease portal pressure
Drug: Propranolol
upto 320mg/day maximum


Ages Eligible for Study:   2 Years to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with Non Cirrhotic Portal Hypertension (NCPH) presenting to our Liver Diseases Follow-up Clinic with history of hemetemesis and/or malena within the past 6 weeks and proven to have esophageal varices as the bleeding source on upper GI endoscopy

Exclusion Criteria:

  • A history of surgery for portal hypertension
  • Patients already on a EST, EVL, or glue injection program before presenting to our hospital
  • Patients already on beta blockers for primary prophylaxis of variceal bleed
  • Severe cardiopulmonary or renal disease
  • Bradycardia (basal heart rate, <50 beats per minute [bpm]) or complete heart block
  • A history of severe side effects or contraindications to β- blockers, like bronchial asthma, diabetes mellitus, heart failure, peripheral vascular disease, prostatic hypertrophy, or arterial hypotension (systolic blood pressure <90 mm Hg)
  • Refusal to give informed written consent to participate in the trial
  • Patients bleeding from gastric varices or Portal Hypertensive Gastropathy (PHG).
  • Patients who had a failure of primary hemostasis during acute bleed were also excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01000779

Department of Gastroenterology, GB Pant Hospital,
New Delhi, Delhi, India, 110002
Sponsors and Collaborators
Govind Ballabh Pant Hospital
Principal Investigator: Shiv K Sarin, MD, DM G.B. Pant Hospital, New Delhi, India
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Shiv K Sarin, G.B. Pant Hospital, New Delhi, India Identifier: NCT01000779     History of Changes
Other Study ID Numbers: NG001
Study First Received: October 22, 2009
Last Updated: December 21, 2010

Keywords provided by Govind Ballabh Pant Hospital:
Non Cirrhotic Portal Hypertension, secondary prophylaxis

Additional relevant MeSH terms:
Hypertension, Portal
Vascular Diseases
Cardiovascular Diseases
Liver Diseases
Digestive System Diseases
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Vasodilator Agents processed this record on August 17, 2017